Other pathways that have beenimplicated in SOX2 regulation in the developing lung, including FGF10,WNT/beta-Catenin signaling, and TTF1 (Que et al.,2007; Gontan et al., 2008; Hashimoto et al., 2012), had relatively modesteffects on its induction following erlotinib treatment in EGFR-mutant cancer cells(Figure 7—figure supplement 4),pointing to FOXO6 as the dominant pathway in this model of oncogene-dependentsignaling. This evidence concerns the gene SOX2 and cancer.